Tapimmune Inc.   Report issue

Contributed to NME For profit Phase 1 Phase 2
Founded: Jacksonville FL United States (1999)
Status: Acquired by Marker Therapeutics (2018)

Organization Overview

First Clinical Trial
2012
NCT01632332
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Breast Neoplasms, Male (Phase 1)

Carcinoma, Ovarian Epithelial (Phase 2)

Hypersensitivity (Phase 2)

Ovarian Neoplasms (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 7